Corbus Pharmaceuticals Reports First Quarter 2023 Financial Results and Provides Corporate UpdatePRNewsWire • 05/09/23
Corbus Pharmaceuticals to Present Latest Pre-Clinical Data on CRB-601 avβ8 Blocking Antibody at the New York Academy of Sciences' Frontiers in Cancer Immunotherapy MeetingPRNewsWire • 05/01/23
Corbus Pharmaceuticals Hosting Virtual 'Meet the Expert' Series: Blocking TGFβ with CRB-601--a New Play for an Old TargetPRNewsWire • 04/18/23
Corbus Pharmaceuticals Presents Latest Pre-Clinical Data on CRB-601 at the 2023 American Association for Cancer Research Annual MeetingPRNewsWire • 04/17/23
Corbus Pharmaceuticals Data on CRB-601 avβ8 Blocking Antibody Accepted for Presentation at the America Association for Cancer Research Annual MeetingPRNewsWire • 03/14/23
Corbus Pharmaceuticals Reports Fourth Quarter 2022 and Year-End Financial Results and Provides Corporate UpdatePRNewsWire • 03/07/23
Corbus Pharmaceuticals Expands Board of Directors with Appointment of Yong Ben, M.D., MBAPRNewsWire • 03/06/23
Corbus Pharmaceuticals to Present at the Oppenheimer 33rd Annual Healthcare ConferencePRNewsWire • 03/02/23
Corbus Pharmaceuticals expands oncology pipeline with the addition of a clinical stage Nectin-4 targeting Antibody Drug Conjugate (ADC)PRNewsWire • 02/13/23
Corbus Presents Latest Preclinical Data for CRB-601 at the Society for Immunotherapy of Cancer (SITC) 37th Annual MeetingPRNewsWire • 11/10/22
Corbus Pharmaceuticals Reports Third Quarter 2022 Financial Results and Provides Corporate UpdatePRNewsWire • 11/08/22
Corbus Pharmaceuticals to Present Pre-Clinical Data for CRB-601 at the Society for Immunotherapy of Cancer (SITC) 37th Annual MeetingPRNewsWire • 10/14/22
Corbus Presents First Pre-Clinical Data for CRB-913 at the European Association for the Study of Diabetes 2022 Annual ConferencePRNewsWire • 09/22/22
Corbus Pharmaceuticals to Present Virtually at the H.C. Wainwright 24th Annual Global Investment ConferencePRNewsWire • 09/12/22
Corbus Pharmaceuticals (CRBP) Reports Q2 Loss, Lags Revenue EstimatesZacks Investment Research • 08/09/22
Corbus Pharmaceuticals Reports Second Quarter 2022 Financial Results and Provides Corporate UpdatePRNewsWire • 08/09/22
Corbus Presents Latest Preclinical Data for CRB-601 at the New York Academy of Sciences Frontiers in Cancer Immunotherapy ConferencePRNewsWire • 05/11/22
Corbus Pharmaceuticals (CRBP) Reports Q1 Loss, Lags Revenue EstimatesZacks Investment Research • 05/10/22
Corbus Pharmaceuticals Reports First Quarter 2022 Financial Results and Provides Corporate UpdatePRNewsWire • 05/10/22
Corbus Presents First Preclinical Data for CRB-601 at the American Association for Cancer Research (AACR) Annual MeetingPRNewsWire • 04/08/22